ABBV · NYSE · CIK 0001551152

AbbVie Inc.

AbbVie Inc.’s most recent SEC filing in our snapshot is a Form 3 filed on Oct 23, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $61.2B and net income of $4.2B, according to its XBRL data on EDGAR. Its EDGAR record lists 42 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$61.2B
Net income, FY2025
$4.2B
Form 4 filings on record, past 12 months
42

Company overview

Legal name (as filed)
AbbVie Inc.
Ticker
ABBV
SEC Central Index Key (CIK)
0001551152
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NORTH CHICAGO, IL
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#20 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from AbbVie Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$56.2BFY2021$58.1BFY2022$54.3BFY2023$56.3BFY2024$61.2BFY2025
Net income
$11.5BFY2021$11.8BFY2022$4.9BFY2023$4.3BFY2024$4.2BFY2025
ABBV annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$56.2B$58.1B$54.3B$56.3B$61.2B
Net income$11.5B$11.8B$4.9B$4.3B$4.2B
Diluted EPS$6.45$6.63$2.72$2.39$2.36
Total assets$146.5B$138.8B$134.7B$135.2B$134.0B
Cash and equivalents$9.7B$9.2B$12.8B$5.5B$5.2B

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ABBV latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 20, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 15, 20268-KDirector or officer change· period Oct 14, 2026Document · Index
Mar 23, 2026DEF 14ADefinitive proxy statement· period May 8, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about AbbVie Inc., by form type:

4 ×188-K ×11144 ×2424B5 ×210-Q ×23 ×1FWP ×111-K ×1SD ×1SCHEDULE 13G ×1
ABBV recent filings
FiledFormWhat it isOriginal
Oct 23, 20263Initial statement of beneficial ownership· period Oct 14, 2026Document · Index
Oct 15, 20268-KDirector or officer change· period Oct 14, 2026Document · Index
Oct 5, 20268-KResults of operations· period Oct 5, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 3, 20268-KRegulation FD disclosure· period Sep 3, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 18, 20268-KOther events· period Aug 18, 2026Document · Index
Aug 14, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 2026424B5424B5Document · Index
Aug 5, 20268-KOther events· period Aug 4, 2026Document · Index
Aug 5, 2026FWPFWPDocument · Index
Aug 4, 2026424B5424B5Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 31, 20268-KResults of operations· period Jul 31, 2026Document · Index
Jul 6, 20268-KResults of operations· period Jul 6, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jun 24, 202611-KAnnual report of employee stock plans· period Dec 31, 2025Document · Index
Jun 22, 20268-KRegulation FD disclosure· period Jun 18, 2026Document · Index
Jun 1, 2026SDSpecialized disclosure report (conflict minerals)Document · Index
May 26, 2026144Notice of proposed sale of securitiesDocument · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 12, 20268-KShareholder vote results· period May 8, 2026Document · Index
May 12, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 8, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 29, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 29, 20268-KResults of operations· period Apr 29, 2026Document · Index
Apr 3, 20268-KResults of operations· period Apr 3, 2026Document · Index
Apr 2, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 31, 2026Document · Index
Apr 2, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 31, 2026Document · Index

Insider filing activity

42 Form 4 filings appear in AbbVie Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Illinois

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001551152 and XBRL company facts. AbbVie Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.